Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.06M Sell
72,400
-92,700
-56% -$1.36M ﹤0.01% 7530
2025
Q4
$2.09M Sell
165,100
-247,800
-60% -$3.66M ﹤0.01% 5828
2025
Q3
$6.35M Sell
412,900
-38,000
-8% -$613K ﹤0.01% 3938
2025
Q2
$7.09M Buy
450,900
+297,800
+195% +$4.51M ﹤0.01% 3531
2025
Q1
$2.92M Buy
153,100
+127,800
+505% +$2.8M ﹤0.01% 4807
2024
Q4
$603K Buy
25,300
+11,300
+81% +$315K ﹤0.01% 8149
2024
Q3
$392K Sell
14,000
-91,900
-87% -$2.6M ﹤0.01% 8763
2024
Q2
$2.77M Buy
105,900
+70,600
+200% +$1.47M ﹤0.01% 4716
2024
Q1
$772K Sell
35,300
-250,700
-88% -$5.37M ﹤0.01% 7465
2023
Q4
$6.65M Sell
286,000
-31,000
-10% -$624K ﹤0.01% 3406
2023
Q3
$6.25M Buy
317,000
+250,600
+377% +$4.94M ﹤0.01% 3315
2023
Q2
$1.51M Sell
66,400
-18,400
-22% -$371K ﹤0.01% 5676
2023
Q1
$1.67M Sell
84,800
-127,000
-60% -$2.44M ﹤0.01% 5717
2022
Q4
$3.64M Buy
+211,800
New +$3.76M ﹤0.01% 4422

Other funds holding RXO

Citadel Advisors's RXO Position: Q1 2026 in Review

Citadel Advisors increased its RXO (RXO) stake by 49% in Q1 2026, buying an estimated $3.41M and bringing the position to 706,497 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3211.

Citadel Advisors first reported a position in RXO in Q4 2022 and has held it in 9 quarters since. 275 funds tracked by Wall St. Rank hold RXO as of Q1 2026.

  • Citadel Advisors held 706,497 shares of RXO worth $10.3M as of Q1 2026.
  • Citadel Advisors bought 232,422 RXO shares in Q1 2026, an estimated $3.41M.
  • RXO made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3211 holding.
  • Citadel Advisors first reported a position in RXO in Q4 2022 and has held it in 9 quarters since.
  • 275 funds tracked by Wall St. Rank held RXO as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.